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To determine the inhibitory profile of the novel somatostatin
(SRIF) analog SOM230 with broad SRIF receptor binding, we
compared the in vitro effects of SOM230, octreotide (OCT), and
SRIF-14 on hormone release by cultures of different types of
secreting pituitary adenomas. OCT (10 nM) significantly in-
hibited GH release in seven of nine GH-secreting pituitary
adenoma cultures (range, 26 to 73%), SOM230 (10 nM) in
eight of nine cultures (range, 22 to 68%), and SRIF-14 (10
nM) in six of six cultures (range,30 to75%). The sst analysis
showed predominant but variable levels of somatostatin re-
ceptor (sst)2 and sst5 mRNA expression. In one culture com-
pletely resistant to OCT, SOM230 and SRIF-14 significantly
inhibited GH release in a dose-dependent manner with an IC50
value in the low nanomolar range. In the other cultures,
SOM230 showed a lower potency of GH release inhibition
(IC50, 0.5 nM), compared with OCT (IC50, 0.02 nM) and SRIF-14
(IC50, 0.02 nM). A positive correlation was found between sst2
but not sst5 mRNA levels in the adenoma cells and the inhib-
itory potency of OCT on GH release in vivo and in vitro, and
the effects of SOM230 and SRIF-14 in vitro. In three prolacti-
noma cultures, 10 nM OCT weakly inhibited prolactin (PRL)
release in only one (28%), whereas 10 nM SOM230 signifi-
cantly inhibited PRL release in three of three cultures (23,
51, and 64.0%). The inhibition of PRL release by SOM230
was related to the expression level of sst5 but not sst2 mRNA.
Several conclusions were reached. First, SOM230 has a broad
profile of inhibition of tumoral pituitary hormone release in
the low nanomolar range, probably mediated via both sst2 and
sst5 receptors. The higher number of responders of GH-
secreting pituitary adenoma cultures to SOM230, compared
with OCT, suggest that SOM230 has the potency to increase
the number of acromegalic patients which can be biochemi-
cally controlled. Second, compared with OCT, SOM230 is more
potent in inhibiting PRL release by mixed GH/PRL-secreting
adenoma and prolactinoma cells. (J Clin Endocrinol Metab 89:
1577–1585, 2004)
CURRENT TREATMENT OPTIONS in patients with ac-romegaly due to a GH-secreting pituitary adenoma
are surgery, medical therapy, and radiotherapy. As medical
therapy, stable somatostatin (SRIF) analogs, such as oct-
reotide (OCT) and the sustained-release depot formulations
Sandostatin-LAR and SR-lanreotide are widely used, both as
primary or secondary therapy (1). Treatment with this gen-
eration of octapeptide SRIF analogs results in clinical and
biochemical control, i.e. normalization of circulating GH and
IGF-I levels, in approximately two thirds of the acromegalic
patients (1). The successful medical treatment of acromegaly
with octapeptide SRIF analogs is due to the expression of
high-affinity (density) SRIF receptors on the adenoma cells,
mainly somatostatin receptor (sst)2, which is one of the five
known SRIF receptor subtypes, sst1–5, and the selective high-
affinity binding of these analogs to the sst2 subtype (2). The
molecular basis for the clinical experience that one third of
patients with acromegaly are not adequately controlled by
treatment with octapeptide SRIF analogs is probably formed
by a variable expression of sst1–5 in the adenomas of these
patients (3–9). Several groups have demonstrated that sst2
and sst5 receptors are the most important sst involved in the
regulation of GH secretion (2, 9). Using sst selective SRIF
analogs, it was shown that, in adenomas that were poorly
responsive to the sst2 selective agonists OCT and lanreotide,
sst5 selective or sst2-sst5 bispecific compounds were able to
suppress GH release more potently (10, 11).
These observations initiated the development of novel sta-
ble SRIF analogs with a more universal sst binding profile.
One of these new compounds, SOM230, was recently shown
to reduce circulating IGF-I levels in rats by 75% after 126 d
of continuous infusion. This effect was significantly more
potent, compared with OCT, which suppressed IGF-I release
under the same experimental condition by only 28% (12). In
rats, the terminal elimination half-life was 23 h, which is
approximately 11 times longer, compared with OCT (12).
Finally, in both cynomolgus monkeys and beagle dogs, in-
fusion of SOM230, and to a much lesser extent OCT (SMS
201–995), lowered IGF-I levels potently (13). Compared with
OCT, SOM230 has a 30, 5, and 40 times higher binding
affinity to sst1, sst3, and sst5 receptors, respectively, and 2.5
Abbreviations: DA, Dopamine; hprt, hypoxanthine-phosphoribosyl-
transferase; OCT, octreotide; PRL, prolactin; SRIF, somatostatin; sst,
somatostatin receptor.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the en-
docrine community.
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(4):1577–1585
Printed in U.S.A. Copyright © 2004 by The Endocrine Society
doi: 10.1210/jc.2003-031344
1577
times lower affinity to sst2 (Ref. 12 and Table 1). This universal
binding profile of SOM230 to sst, in combination with the im-
portance of sst2 and sst5 receptors in regulating GH secretion by
pituitary adenoma cells, was the rationale for the present study
to evaluate, for the first time, the effects of SOM230, OCT, and
the native SRIF molecule SRIF-14 on hormone secretion by
human GH-secreting pituitary adenomas. Moreover, recent ev-
idence suggests that sst5 receptors are also involved in the
regulation of prolactin (PRL) secretion by human prolactinoma
cells (11, 14). Therefore, we compared the effects of OCT and
SOM230 on PRL secretion by primary cultures of human pro-
lactinomas. A correlation is made with the sst subtype expres-
sion patterns in the adenoma cells.
Patients and Methods
Patients
Pituitary tumor samples were obtained by transsphenoidal operation
from nine patients with GH-secreting pituitary adenomas and from
three patients with prolactinomas as described in detail previously (15).
Diagnosis was made on the basis of clinical and biochemical character-
istics of the patients, in combination with (immuno)histochemistry of the
tumor samples (Table 2). All patients gave their informed consent for the
use of tumor material for research purposes. Directly after obtaining the
tissue, a piece of tissue was snap frozen on dry ice and stored at 80 C
until analysis. The remaining tissue was used for cell culture.
To evaluate in vivo responsiveness to OCT, patients received at 0900 h
a single sc injection of 100 g OCT. Blood samples were collected 30 min
before and 1 min before, and hourly until 0800 h after sc injection. At the
same time points, blood samples were taken at a control day. The effect
of OCT on circulating GH levels was determined by calculating the mean
GH suppression between 2 and 8 h after sc injection, compared with the
same period of time on a control day.
Quantitative PCR
Quantitative PCR was performed as described previously (16).
Briefly, poly A mRNA was isolated using Dynabeads Oligo (dT)25
(Dynal AS, Oslo, Norway) from freshly isolated pituitary adenoma
cell pellets containing 0.5–1.0  106 adenoma cells. Analysis of sst
subtype mRNA levels in both tissue or freshly isolated cell pellets
(n  4) yielded comparable results (data not shown). cDNA was
synthesized using the poly A mRNA, which was eluted from the
beads in 40 l H2O for 10 min at 65 C, using Oligo (dT)12–18 primer
(Invitrogen, Breda, The Netherlands). One twentieth of the cDNA
library was used for quantification of sst subtype mRNA levels. A
quantitative PCR was performed by TaqMan Gold nuclease assay
(Perkin-Elmer Corp., Foster City, CA) and the ABI PRISM 7700 se-
quence detection system (Perkin-Elmer) for real-time amplifications,
according to manufacturer’s protocol. The assay was performed using
15 l TaqMan Universal PCR master mix (Applied Biosystems,
Capelle aan de ijssel, The Netherlands), 500 nm forward primer, 500
nm reverse primer, 100 nm probe and 10 l cDNA template, in a total
reaction volume of 25 l. The reactions were carried out in a ABI 7700
sequence detector (Perkin-Elmer, Groningen, The Netherlands). After
an initial heating at 95 C for 8 min, samples were subjected to 40 cycles
of denaturation at 95 C for 15 sec and annealing for 1 min at 60 C. The
primer and probe sequences that were used are indicated below. The
detection of hypoxanthine-phosphoribosyl-transferase (hprt) mRNA
served as a control and was used for normalization of the sst subtype
mRNA levels.
The primer sequences that were used included the following: hprt
forward, 5-TGCTTTCCTTGGTCAGGCAGTAT-3; hprt reverse, 5-
TCAAATCCAACAAAGTCTGGCTTATATC-3; sst1 forward,5-TGAG-
TCAGCTGTCGGTCATC-3; sst1 reverse, 5-ACACTGTAGGCACG-
GCTCTT-3; sst2 forward, 5-TCGGCCAAGTGGAGGAGAC-3; sst2
reverse, 5-AGAGACTCCCCACACAGCCA-3; sst3 forward, 5-CT-
GGGTAACTCGCTGGTCATCTA-3; sst3 reverse, 5-AGCGCCAGGT-
TGAGGATGTA-3; sst5 forward, 5-CATCCTCTCCTACGCCAACAG-
3; and sst5 reverse, 5-GGAAGCTCTGGCGGAAGTT-3.




CAGCCCTTCAGTCACCAAC-TAMRA-3; and sst5, 5-FAM-CCCGT-
CCTCTACGGCTTCCTCTCTGA-TAMRA-3.
Primers and probes were purchased from Biosource (Nivelles,
Belgium).
The relative amount of sst subtype mRNA was determined using a
TABLE 1. Binding affinity of SRIF-14, OCT, and SOM230 for the five human sst, sst1–5
Compound hsst1 hsst2 hsst3 hsst4 hsst5
SRIF-14 0.93  0.12 0.15  0.02 0.56  0.17 1.5  0.4 0.29  0.04
OCT 280  80 0.38  0.08 7.1  1.4 1000 6.3  1.0
SOM230 9.3  0.1 1.0  0.1 1.5  0.3 100 0.16  0.01
Data are reproduced with permission (12). Results are the mean  SE; IC50 values are expressed in nanomolar concentration.
TABLE 2. Patient and hormone data of the 12 patients with pituitary adenoma





In vitro hormone release
GH (ng/105 cells72 h) PRL (ng/105 cells72 h)
GH-secreting adenoma
1 M 58 9.8 19 175 520  24 1192  60
2 M 26 31 111 201 547  7 492  7
3 F 60 5.4 39 66 372  13 1105  71
4 F 55 15 19 184 1021  19 
5 M 36 118 24 111 336  35 
6 F 44 14 15 289 230  10 
7 F 41 72 6.7 285 640  18 
8 F 42 6.8 0.9 88.3 55  2 21  2
9 F 65 6.8 9.3 169 246  9 156  5
Prolactinoma
10 F 35 2000  5638  143
11 F 64 13520  1486  80
12 F 37 32  1700  50
Normal range for IGF-I, 12–40 nmol/liter. M, Male; F, female; , not detectable.
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standard curve generated from known amounts of human genomic
DNA. For determination of the amount of hprt mRNA, a standard curve
was generated of a pool of cDNAs from a human cell line known to
express hprt. The linear range of amplification ranged between 4 log
dilutions of genomic DNA or cDNA, respectively. The relative amount
of sst subtype mRNA was calculated relative to the amount of hprt
mRNA and is given in arbitrary units. Each sample was assayed in
duplicate.
Cell dispersion and cell culture
Single-cell suspensions of the pituitary adenoma tissues were pre-
pared by enzymatic dissociation with dispase as described in detail
previously (15). For short-term incubation of monolayer cultures, the
dissociated cells were plated in 48-well plates (Corning, Cambridge,
MA) at a density of 105 cells per well per 1-ml culture medium. After
3– 4 d the medium was changed and 72-h incubations without or with
test substances were initiated. At the end of the incubation, the
medium was removed and centrifuged for 5 min at 600  g. The
supernatant was collected and stored at 20 C until analysis.
The choice for a 72-h incubation was made on the basis of previous
studies, in which we demonstrated that exposure of GH-secreting pi-
tuitary adenoma cells for 4–96 h to octreotide showed a variable, but in
all instances during longer incubations statistically significant inhibition
of GH release, which paralleled the sensitivity of GH secretion to oct-
reotide in vivo (17). For long-term incubation studies in Transwells (18),
the isolated tumor cells were plated in Transwell-COL membranes
(Corning) at a density of 105 cells/well. The Transwells were then placed
into multiwell plates (24-well, Corning) containing 1 ml culture medium.
After 72 h the Transwells were transferred to wells containing fresh
medium (without or with test substances). Every 3–4 d the cells were
placed into fresh medium and the incubation media were collected and
stored at 20 C until determination of hormone concentrations.
The cells were cultured at 37 C in a CO2 incubator. The culture
medium consisted of MEM supplemented with nonessential amino ac-
ids, sodium pyruvate (1 mmol/liter), 10% fetal calf serum, penicillin (1
105 U/liter), fungizone (0.5 mg/liter), l-glutamine (2 mmol/liter), and
sodium bicarbonate (2.2 g/liter, pH 7.6). Media and supplements were
obtained from Gibco Bio-cult Europe (Invitrogen, Breda, The
Netherlands).
Unfortunately, generally not enough tumor material was obtained to test
for each tumor the dose dependency of effects for the indicated drugs.
Hormone determinations
Human GH and PRL concentrations in the media and cell extracts
were determined by a nonisotopic, automatic chemiluminescence im-
munoassay system (Immulite; Diagnostic Products Corp. Inc., Los An-
geles, CA). Intra- and interassay coefficients of variation for GH and PRL
were 6.0 and 5.7% and 6.2 and 6.4%, respectively. ACTH, LH, and FSH
concentrations in the culture media were determined as well to exclude
the presence of contaminating normal pituitary cells in the cultures.
Human ACTH, LH, and FSH concentrations were determined by a
nonisotopic, automatic chemiluminescence immunoassay system (Im-
mulite, Diagnostic Products Corp. Inc.). Intra- and interassay coefficients
of variation for ACTH, LH, and FSH were 5.6, 5.7, and 6.4% and 7.8, 12.3,
and 7.5%, respectively. Except for the expected hormones GH and PRL,
none of the other hormones were detectable (not shown).
Test substances
OCT (Sandostatin) and bromocriptine were obtained from Novartis
Pharma A.G. (Basel, Switzerland). SOM230 was provided by Novartis
Pharma A.G. Somatostatin-14 (SRIF-14) was purchased from Sigma
Chemical Co. (St. Louis, MO).
Statistical analysis of the data
All data on hormone release are expressed in mean se, n 4 wells
per treatment group. All data were analyzed by ANOVA to determine
overall differences between treatment groups. When significant differ-
ences were found by ANOVA, a multiple comparison between treat-
ment groups was made using the Newman-Keuls test. Correlation anal-
ysis was done by the use of the Spearman’s rank correlation test.
Calculation of IC50 values for inhibition of hormone release were made
using GraphPad Prism (San Diego, CA).
FIG. 1. Relative sst1, sst2, sst3, and sst5
mRNA expression levels in GH-secret-
ing pituitary adenomas. Values are ex-
pressed as the number of copies of the
respective sst mRNAs, relative to the
number of copies of hprt. nd, Not de-
tectable. Note the differences in the
scale of the y-axis between sst1, sst2,
and sst3 mRNA levels on the one hand,
and the higher sst5 mRNA levels on the
other hand. The relative amount of sst
subtype mRNA was calculated relative
to the amount of hprt mRNA and is
given in arbitrary units.
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Results
Sst subtype mRNA expression and correlation with in vivo
GH suppression by octreotide
In seven of nine GH-secreting pituitary adenoma sam-
ples the sst subtype mRNA expression pattern was deter-
mined. Figure 1 shows that two adenomas expressed sst1
mRNA, three adenomas expressed sst3 mRNA and that all
adenomas expressed sst2 and sst5 mRNAs. Expression of
sst mRNAs was variable between adenoma samples. The
difference between the lowest and the highest level mea-
sured, amounted to 7-, 8-, 3-, and 5-fold for sst1, sst2, sst3,
and sst5, respectively. The sst subtype mRNA levels
showed no statistical correlation (data not shown). The
mean percentage in vivo GH suppression (range 18 and
91% suppression) between 2 and 8 h after the adminis-
tration of a single sc dose of 100 g OCT (patients 1, 2, 3,
5, 6, and 7) was positively correlated with sst2 mRNA
expression levels (Fig. 2, left panel) but not with sst5 mRNA
levels (Fig. 2, right panel).
Effects of SS analogs on GH secretion
In most GH-secreting pituitary adenomas, the effect of 10
nm OCT, SOM230, or SRIF-14 on GH release was evaluated
in parallel in vitro. Figure 3 shows that GH release was
significantly suppressed by OCT in seven of nine cultures, by
SOM230 in eight of nine cultures and by SRIF-14 in six of six
cultures. In the majority of the adenomas, the percentage
suppression using a maximally active concentration of the
three compounds, was comparable. Only the adenoma cells
of patient 7 showed a dissociated response to OCT on the one
hand and to SOM230 and SRIF-14 on the other hand. In this
adenoma culture, GH release was not inhibited by OCT,
whereas both SOM230 and SRIF-14 induced a statistically
significant suppression of GH release. In the respective pa-
tient, OCT (100 g sc) did not suppress GH concentrations
as well. As seen in Fig. 3, the response in terms of GH
suppression was variable between the individual adenoma
cultures. This variable responsiveness to OCT and SOM230
correlated well with the sst2 mRNA expression levels in the
adenoma cells of the respective patients (Fig. 4, upper panel).
Comparable to the patients responsiveness to OCT, sst5
mRNA expression showed no statistically significant corre-
lation with the percentage of GH suppression by 10 nm OCT.
Interestingly, the effects of 10 nm SOM230, which shows a
more universal binding profile for sst receptors, including
high-affinity binding to sst5, also showed no correlation with
sst5 mRNA expression levels. This is demonstrated in Fig. 4
(lower panel).
In several adenoma cultures, the dose-response relation-
ship of the inhibitory effects of OCT, SOM230, and SRIF-14
could be evaluated. Figure 5 (right panel) shows the effects of
the three compounds on GH release by the adenoma cells of
patient 7, which did not respond to OCT. The adenoma cells
of this patient had the lowest sst2 mRNA levels of all cases
studied (Fig. 1, upper right panel). As shown, GH release by
the cells of this patient was inhibited in a dose-dependent
manner by both SOM230 and SRIF-14. The IC50 values for the
inhibition of GH release were 0.5 and 0.6 nm for SOM230 and
SRIF-14, respectively. In the other adenoma cultures, both
OCT and SRIF-14 were slightly more efficacious, in terms of
IC50 values, compared with SOM230. Figure 5 (left panel)
shows the mean dose response of OCT, SOM230, and SRIF-14
for the other cultures. Mean IC50 values were 0.02, 0.5, and
0.02 nm for OCT, SOM230, and SRIF-14, respectively.
FIG. 2. Correlation between sst2 and sst5 mRNA levels and the in vivo response of GH release to a single sc injection of 100 g OCT in six
acromegalic patients. The relative amount of sst subtype mRNA was calculated relative to the amount of hprt mRNA and is given in arbitrary
units.
FIG. 3. Effects of OCT (10 nM; open bars), SOM230 (10 nM; filled
bars), and SRIF-14 (10 nM; hatched bars) on GH release by nine
cultured GH-secreting pituitary adenomas. The results are expressed
as the percentage inhibition of GH release, compared with untreated,
control cells. *, P  0.01 vs. untreated control cells. nd, Not done.
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Effects of somatostatin (SS) analogs on PRL secretion
Because previous studies demonstrated the involvement
of sst5 receptors in regulating PRL release, we also compared
the effects of OCT and SOM230 on PRL release. Five ade-
noma cultures cosecreted PRL as well. OCT (10 nm) and
SOM230 (10 nm) significantly inhibited PRL release in four
of five and five of five cultures, respectively (Fig. 6). The
percentage suppression was between 16 and 66% for OCT
and between 38 and 74% for SOM230, indicating its higher
efficacy. In four of five cultures (no. 1, 3, 8, and 9), SOM230
was significantly more potent with regard to its maximal
suppressive effect on PRL release, when compared with OCT
(P  0.01).
In addition to mixed GH/PRL-secreting pituitary adeno-
mas, we also compared the effects of OCT and SOM230 on
PRL release in three primary human prolactinoma cultures
(no. 10, 11, and 12) (Table 2). Figure 7 shows that prolacti-
noma no.10 selectively expresses a high level of sst5 mRNA,
whereas prolactinoma 11 expressed sst1 mRNA but very low
sst5 mRNA. In agreement with the low affinity of OCT for sst5
and the very high affinity of SOM230 for this sst, 10 nm OCT
did not significantly inhibit PRL release by the two prolacti-
noma cultures, whereas 10 nm SOM230 potently suppressed
(49%) PRL release by cells of adenoma 10 (high sst5) and
slightly (23%) by cells of prolactinoma no.11 (low sst5).
Both adenoma cultures showed high sensitivity to 10 nm of
FIG. 4. Correlation between sst2 (upper panel) and sst5 (lower panel) mRNA levels and the percentage suppression of GH release induced by
SOM230 (10 nM) and OCT (10 nM). The relative amount of sst subtype mRNA was calculated relative to the amount of hprt mRNA and is given
in arbitrary units.
FIG. 5. Dose-dependent inhibition of
GH release by SOM230 (), OCT (f),
and SRIF-14 (E) in cultured pituitary
adenoma cells. The left panel represents
the mean dose-dependent effects of
SOM230 (n  5; adenoma no. 2, 3, 4, 5,
and 6), OCT (n 4; adenoma no. 2, 3, 5,
and 6), and SRIF-14 (n  4; adenoma
no. 2, 3, 5, and 6). The right panel shows
the dose-dependent inhibitory effects of
the compounds on GH release by cells
patient 7.
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the dopamine agonist bromocriptine (73 and 89% inhi-
bition in cultures 10 and 11, respectively). In one prolacti-
noma culture (no. 12) the long-term in vitro effects of OCT,
SOM230, and bromocriptine were studied. Figure 8 shows
that both SOM230 (10 nm) and bromocriptine (10 nm) sup-
pressed PRL release by approximately 90% after 9 d of con-
tinuous incubation with the compounds. In this particular
adenoma, OCT was only slightly effective (30% after 9 d).
Unfortunately, not enough tissue was obtained from this
patient to study the sst subtype expression pattern.
Discussion
SRIF receptor expression on GH-secreting pituitary ade-
nomas forms the basis for successful treatment of acrome-
galic patients using sst2-selective octapeptide SRIF-analogs
(19, 20). Recent in vitro studies have demonstrated that both
sst2 and sst5 receptors are involved in the regulation of GH
release by normal human fetal anterior pituitary cells and
GH-secreting pituitary adenoma cells (2, 9, 11). In addition,
evidence exists that sst5 exclusively regulates PRL secretion
from human prolactinoma cells (11, 14). Moreover, BIM-
23244, a SRIF analog with high-affinity binding to sst2 and
sst5 receptors, was shown to achieve a better suppression of
GH secretion by cultured GH-secreting pituitary adenomas
that were partially responsive to OCT, suggesting that such
bispecific SS analogs could achieve a better control of GH
secretion in a larger number of acromegalic patients (10). The
recent observation that sst subtypes may form homo- and
heterodimers, resulting in receptors with enhanced binding
affinity and modified functional properties (21, 22), may
form one of the explanations for the enhanced efficacy of
bispecific compounds such as BIM-23244. In addition, an sst2
antagonist was shown to inhibit the GH suppressing action
of sst2/sst5 biselective agonists in human fetal pituitary cells,
supporting the concept of functional interaction between sst2
and sst5 receptors in the regulation of GH secretion (23).
FIG. 6. Effect of 10 nM OCT (open bars) or 10 nM SOM230 (filled bars)
on PRL secretion by mixed GH/PRL-secreting pituitary adenomas.
The results are expressed as the percentage inhibition of PRL release,
compared with untreated, control cells. *, P  0.01 vs. untreated
control cells.
FIG. 7. Upper panel, Effects of SOM230
(10 nM), OCT (10 nM), and bromocrip-
tine (10 nM) on PRL release by two cul-
tured prolactinomas (no. 10 and 11).
*, P  0.01 vs. untreated control cells
(incubation time 72 h). Lower panel, sst
subtype mRNA expression in the ade-
noma cells of patient 10 and 11.
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Recently a novel stable SRIF analog, with a more universal
binding profile and high-affinity binding to sst1, sst2, sst3,
and sst5, was introduced (12, 13). This SRIF analog, SOM230,
was shown to be significantly more potent in lowering IGF-I
levels in rats, compared with the sst2-preferring analog OCT
(12). SOM230 has a favorable elimination half-life of 23 h (12),
suggesting that this analog may be suitable for clinical ap-
plication as well (24). On the basis of the involvement of
sst2/sst5 receptors in regulating GH secretion and sst5 re-
ceptors in regulating PRL secretion, we compared in the
present study the efficacy of SOM230 in the regulation of GH
and PRL release by primary cultures of human pituitary
adenoma cells.
In agreement with previous studies (3–10), we found a
variable expression of sst mRNAs, predominantly sst2 and
sst5, in our series of GH-secreting pituitary adenomas. Only
selected cases expressed sst1 and sst3 mRNAs, suggesting
that these sst subtypes are probably of less importance in this
type of pituitary adenoma. Moreover, in most adenomas, sst5
expression levels were relatively higher, compared with sst2
mRNA levels. On the other hand, the preoperative response
of acromegalic patients to a single sc administration of 100g
OCT was positively correlated with the sst2 mRNA, but not
with sst5 mRNA levels, in the pituitary adenomas of the
patients obtained via transsphenoidal surgery. These data
demonstrate that the sst2 subtype is clearly the predominant
receptor determining in vivo responsiveness to OCT in ac-
romegalic patients.
In agreement with previous observations (10), sst2 mRNA
levels were positively correlated with the in vitro GH sup-
pression by this sst2 selective SRIF analog as well. Surpris-
ingly, although SOM230 shows a very high affinity for sst5
receptors, no significant correlation was found between the
in vitro GH suppression by a maximally active concentration
of SOM230 and sst5 mRNA levels, whereas a positive cor-
relation was found between the effects of SOM230 and sst2
mRNA levels. Although these data were unexpected, a pre-
vious study by Jaquet et al. (9) in fact already made the same
observation using SRIF-14. In this study, sst2 mRNA but not
sst5 mRNA levels in GH-secreting pituitary adenomas
showed a positive correlation with in vitro GH suppression
by 1 nmol/liter SRIF-14.
As suggested by Jaquet et al. (9), it is not known yet
whether the observed sst mRNA levels directly correlate
with sst protein levels. The importance of the sst2 subtype in
regulating GH secretion by the majority of human GH-
secreting pituitary adenomas is also evident by our obser-
vation that the potency of OCT in terms of IC50 values mea-
sured for the inhibition of GH release are slightly higher,
compared with SOM230. Nevertheless, SOM230 shows a
high efficacy to inhibit GH release, with an IC50 value in the
low nanomolar range. In 89% of the cultures SOM230 sig-
nificantly inhibited GH release. In this respect, OCT is
slightly less efficacious, with a significant GH-suppressive
effect in seven of nine cultures (78%). In one OCT-resistant
culture, SOM230 inhibited GH release with an IC50 value
comparable with that of SRIF-14 (IC50, 0.5 and 0.6 nm, re-
spectively), confirming the importance of the sst5 receptor
subtype in mediating GH release, when sst2 levels are low.
However, although SOM230 has a slightly lower potency
(IC50) for the inhibition of GH release in most cases, com-
pared with OCT, its efficacy is higher, compared with OCT,
in terms of the number of responders. Therefore, in addition
to the sst2/sst5 bispecific compound BIM-23244, SOM230
also has the potential to achieve better control of GH hyper-
secretion in a larger number of acromegalic patients. More-
over, the very favorable elimination half-life of SOM230 (12)
makes this compound an interesting candidate for clinical
application as well.
Apart from regulating GH secretion, sst5 receptors play a
regulatory role in normal and tumoral PRL secretion as well
(2, 11, 14). A significant proportion of GH-secreting pituitary
adenomas contain GH- and PRL-expressing cells, either as
individual cells expressing GH or PRL or as mammosoma-
totroph cells expressing GH and PRL in the same cells (25).
In agreement with these data, we observed cosecretion of GH
and PRL in 56% of the cultures and showed that SOM230 has
a potent inhibitory effect on PRL secretion in mixed GH-PRL-
secreting pituitary adenomas and prolactinomas. In four of
five mixed GH-PRL-secreting pituitary adenomas, SOM230
was significantly more potent, compared with OCT, in its
maximal suppressive effect on PRL secretion. Recently it was
shown that activation of sst1 by the sst1-selective agonist
BIM-23296 caused a dose-dependent inhibitory effect in the
nanomolar range on GH and PRL secretion by GH-secreting
pituitary adenomas. In addition to lowering GH and PRL
secretion, this SS-analog induced a decrease in cell viability
as well (26). In our series we found that two of seven ade-
nomas expressed sst1. In selected cases, therefore, sst1 may
play a regulatory role on GH-secreting pituitary adenoma
cell function as well.
In three dopamine (DA) agonist-sensitive prolactinomas,
SOM230 was significantly more potent than OCT in lowering
PRL secretion. In two of the prolactinomas, there was a clear
relationship between the expression of sst5 mRNA in the
adenoma cells and the percentage inhibition of PRL secretion
by SOM230. In one prolactinoma culture, which expressed
FIG. 8. The effect of long-term in vitro incubation with OCT (10 nM),
SOM230 (10 nM), and bromocriptine (10 nM) on PRL release by cul-
tured prolactinoma cells of patient no. 12. The pituitary adenoma cells
were cultured in Transwell tissue culture inserts for 14 d without or
with the compounds indicated. Medium was collected and refreshed
every 3 or 4 d and stored at 20 C until determination of PRL
concentrations. Values are expressed as the percentage of hormone
release of control cells at each time point indicated and are the mean
SEM of four wells per treatment group. , OCT; E, SOM230; f, bro-
mocriptine. *, P  0.01 vs. untreated control cells (incubation time
72 h).
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high levels of sst5 mRNA and no other sst mRNAs, PRL
secretion was reduced to the same extent as that induced by
bromocriptine. One other prolactinoma, which showed a
significantly lower responsiveness to SOM230, had very low
sst5 mRNA levels. The lower potency of OCT in reducing
PRL secretion by prolactinomas seems related to the very low
sst2 levels, as was demonstrated in a series of 10 prolacti-
nomas by Jaquet et al. (14). These data further underline the
role of sst5 in mediating its suppressive effect on PRL secre-
tion. However, the potential clinical importance of these
findings should be considered in view of the very high pro-
portion of patients with prolactinomas responding to DA
agonist treatment with a normalization of PRL levels and
tumor shrinkage (27, 28). In addition, Jaquet et al. (14) pre-
viously showed that the effects of sst5 selective compounds
on prolactinoma cells are superimposable at higher concen-
tration to those of the DA agonists, but not additive, partic-
ularly in adenomas resistant to dopaminergic suppression of
PRL release.
Whereas sst5 receptors may mediate antiproliferative ef-
fects (29), the role of this receptor in the control of pituitary
adenoma cell proliferation is unclear. Indirect evidence for a
role of sst5 in the regulation of human GH-secreting pituitary
adenoma cell proliferation was obtained from the observa-
tion of a germ line mutation (Arg240Trp) in genomic DNA
from pituitary adenoma and peripheral blood mononuclear
cells of an acromegalic patient resistant to SRIF analog treat-
ment and a higher proliferation rate of cells overexpressing
this mutant sst5 receptor, compared with cells expressing
wild-type sst5 (30). Whether activation of sst5 receptors ex-
pressed on human GH-secreting pituitary adenomas and
prolactinomas also mediates an antiproliferative effect in
these cell types remains to be elucidated, however.
Because somatostatin analogs inhibit the secretion of in-
sulin, impaired glucose tolerance was observed after the
acute administration of octreotide (31). Recently we observed
similar glucose responses to the acute administration of
SOM230 in vivo (32). However, SOM230 did not modify
insulin secretion, suggesting another mechanism of action.
The inhibitory effect of octreotide on insulin secretion is
short-lived, and clinically important effects on carbohydrate
metabolism during long-term therapy are not observed (33).
Although the acute rise in glucose levels after SOM230 in-
jection requires further attention, preclinical studies in cyno-
molgus monkeys showed that insulin, glucagon, and glucose
levels remained unchanged after 7 d of high-dose infusion
with SOM230 (13). In addition, 126 d treatment of rats with
pharmacological doses of SOM230 did not modify plasma
glucose levels (12). These data suggest that SOM230 is well
tolerated in rats and monkeys with regard to glucose
homeostasis.
In conclusion, the novel universal SRIF analog SOM230 is
a potent inhibitor of GH and PRL secretion in GH-secreting
pituitary adenomas. The higher number of cultures respond-
ing to SOM230, compared with OCT, suggests that SOM230
has the potential to increase the number of patients con-
trolled biochemically, both via sst2 and sst5. In addition,
SOM230 is more potent in its inhibitory effect on PRL se-
cretion in mixed GH/PRL-secreting pituitary adenomas. In
prolactinoma cultures, sst5 receptors mediate the potent in-
hibitory effects of SOM230 on PRL secretion. Because the
majority of patients with prolactinomas are successfully
treated using DA agonists, there may be a role for SOM230
in the treatment of prolactinoma patients, which are intol-
erant to DA agonists.
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